Clinical Trial Update: Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing camrelizumab to chemotherapy in relapsed/refractory classical Hodgkin lymphoma is underway with status not reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Classical Hodgkin Lymphoma | Phase 3 | Status: UNKNOWN